发明名称 THYMIC STROMAL LYMPHOPOIETIN (TSLP)-BINDING MOLECULES AND METHODS OF USING THE MOLECULES
摘要 The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.
申请公布号 US2017066823(A1) 申请公布日期 2017.03.09
申请号 US201615258683 申请日期 2016.09.07
申请人 EDWARDS Matthew John;RONDEAU Jean-Michel Rene;Miller Danforth;Huang Daniel;KNOPF Hans-Peter;VAN HEEKE Gino Anselmus;HEMMIG Rene;GUPTA Kapil;HAUBST Nicole;ANDLAUER Barbara 发明人 EDWARDS Matthew John;RONDEAU Jean-Michel Rene;Miller Danforth;Huang Daniel;KNOPF Hans-Peter;VAN HEEKE Gino Anselmus;HEMMIG Rene;GUPTA Kapil;HAUBST Nicole;ANDLAUER Barbara
分类号 C07K16/24;A61K47/42;A61K45/06;A61K9/00;A61K47/26;A61K47/22;A61K39/395;A61K47/18 主分类号 C07K16/24
代理机构 代理人
主权项 1. A molecule that specifically binds human thymic stromal lymphopoietin (TSLP) selected from any one of the following: a) a molecule that comprises: a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 4; a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence of SEQ ID NO: 2; a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence of SEQ ID NO: 3; a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO: 11; a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence of SEQ ID NO: 12; and a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence of SEQ ID NO: 13; b) a molecule that comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO: 5; a HCDR2 comprising the amino acid sequence of SEQ ID NO: 6; a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; a LCDR1 comprising the amino acid sequence of SEQ ID NO: 14; a LCDR2 comprising the amino acid sequence of SEQ ID NO: 15; and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; c) a molecule that comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 17; d) a molecule that comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 22, and a light chain comprising the amino acid sequence of SEQ ID NO: 25; e) A molecule that comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9, and a light chain comprising the amino acid sequence of SEQ ID NO: 19; f) A molecule that comprises a paratope comprising at least one of the following residues: Thr28, Asp31, Tyr32, Trp33, Asp56, Glu101, Ile102, Tyr103, Tyr104, Tyr105 of a heavy chain sequence of SEQ ID NO:22 or Gly28, Ser29, Lys30, Tyr31, Tyr48, Asp50, Asn51, Glu52, Asn65, and Trp92 of a light chain sequence of SEQ ID NO:25; g) An antibody fragment that binds human TSLP and comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 4; a HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; a LCDR1 comprising the amino acid sequence of SEQ ID NO: 11; a LCDR2 comprising the amino acid sequence of SEQ ID NO: 12; and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 13;and h) An antibody fragment that binds human TSLP comprises: a HCDR1 comprising the amino acid sequence of SEQ ID NO: 5; a HCDR2 comprising the amino acid sequence of SEQ ID NO: 6; a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; a LCDR1 comprising the amino acid sequence of SEQ ID NO: 14; a LCDR2 comprising the amino acid sequence of SEQ ID NO: 15; and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.
地址 Horsham GB